The Five Numbers That Define Your Cardiac Baseline as a Woman: and Why They Are Not the Same as Your Husband's

At her last physical, she received a lipid panel, a blood pressure reading, and a hemoglobin. The physician said everything was fine. The LDL was 118. Blood pressure was 124/78. Hemoglobin normal.

She does not know her ApoB. She does not know her fasting insulin. She has never had Lp(a) measured. She does not know her hs-CRP. She is 47 and entering perimenopause.

What was measured tells her very little about her actual cardiovascular trajectory. The five numbers below are the ones that do.

Number One: ApoB

What it is: Apolipoprotein B is a protein present on the surface of every atherogenic lipoprotein particle, one molecule per LDL particle, one per VLDL particle, one per IDL particle. The ApoB concentration in blood directly counts the total number of atherogenic particles. 5 / Solid

Why it matters more than LDL: LDL cholesterol measures the cholesterol content of LDL particles, how much cholesterol is packed inside them , not how many particles there are. A woman can have LDL of 115 with ApoB of 110 (high particle number, small dense particles carrying less cholesterol each) or ApoB of 70 (fewer, larger particles). The particle count (ApoB) drives atherosclerotic plaque development more directly than the cholesterol content per particle.

Women with insulin resistance, PCOS, or perimenopausal metabolic changes often have the small dense LDL phenotype: LDL appears moderate, but ApoB is high because there are many small particles. Standard lipid panels miss this pattern entirely.

Targets:

• Below 90 mg/dL: reasonable for most women
• Below 70 mg/dL: appropriate for high-risk women (prior heart attack, diabetes, multiple risk factors, Lp(a) above 50)
• Below 60 mg/dL: considered for very high-risk women

Where LDL misleads women specifically: At menopause, LDL rises 10-15 mg/dL due to estrogen’s loss of LDL receptor upregulation. But LDL may still appear in the “normal” range while ApoB has risen meaningfully. ApoB captures the menopausal dyslipidemia pattern more accurately.

Number Two: Blood pressure (with context)

What it is: The force of blood against artery walls. Systolic (upper number) reflects the force at each heartbeat; diastolic (lower number) reflects pressure between beats.

Why clinic readings are insufficient: Blood pressure fluctuates throughout the day and varies significantly by context. White-coat hypertension (elevated readings in clinical settings, normal elsewhere) and masked hypertension (normal clinic readings, elevated elsewhere) are both common and clinically significant. The nocturnal blood pressure dip, blood pressure falling 10-20% during sleep , is invisible on standard clinic readings and is an independent predictor of cardiovascular events. 5 / Solid

Why it matters differently in women: The menopausal transition produces a rise in blood pressure, particularly diastolic, as estrogen’s vasodilatory and renal sodium-sparing effects decline. Women who were normotensive at 35 may have blood pressure of 132/86 at 48, enough to warrant treatment but perhaps not enough to generate a clinical conversation if the threshold being applied is 140/90.

Target: Below 130/80. The 2017 ACC/AHA guidelines moved the treatment threshold from 140/90 to 130/80, a change that disproportionately reclassifies women as having stage 1 hypertension given the typical perimenopausal pattern of borderline elevation.

How to measure it properly: Morning readings (within 30 minutes of waking, before coffee or medication, after 5 minutes seated rest) and evening readings (after dinner, seated, arm at heart level). Average of 3 readings on 3 different days is more reliable than any single measurement. Home readings provide the context that clinic readings cannot.

Number Three: Fasting insulin

What it is: The insulin level after 8-12 hours of fasting. Reflects how much insulin the pancreas is producing to maintain overnight blood glucose levels.

Why it matters: Insulin resistance is a progressive condition. The sequence: insulin resistance develops (often from visceral fat accumulation, sedentary behavior, or hormonal changes) → the pancreas compensates by producing more insulin → fasting insulin rises → blood glucose is maintained by the higher insulin → eventually, the pancreas cannot fully compensate → fasting glucose begins to rise → prediabetes → diabetes. 5 / Solid

Fasting insulin rises years before fasting glucose. A woman with normal fasting glucose (93 mg/dL) and elevated fasting insulin (18 uIU/mL) has significant insulin resistance that her glucose would not reveal and that a standard metabolic panel would entirely miss.

Insulin resistance drives cardiovascular risk through multiple pathways: elevated triglycerides, reduced HDL, elevated small dense LDL (the same phenotype that elevates ApoB), visceral fat deposition, systemic inflammation, and hypertension.

Target: Below 10 uIU/mL fasting. Below 7 is optimal. Above 10 warrants dietary and lifestyle intervention; above 15 warrants serious metabolic management discussion.

Why it is not routinely ordered: It is not part of standard metabolic panels and requires a separate order. Insurance coverage varies. Many physicians do not routinely check it. Ask for it specifically.

Number Four: hs-CRP

What it is: High-sensitivity C-reactive protein is a marker of systemic inflammation produced by the liver. Elevated hs-CRP reflects chronic low-grade inflammation in arteries, adipose tissue, or the immune system.

Why it matters for cardiovascular risk: The JUPITER trial demonstrated that statin therapy in people with low LDL but elevated hs-CRP (above 2 mg/L) reduced cardiovascular events significantly, providing evidence that hs-CRP identifies cardiovascular risk that standard cholesterol metrics miss. Elevated hs-CRP predicts cardiovascular events independently of cholesterol levels. 5 / Solid

Why it matters specifically for women: Women with inflammatory conditions (autoimmune disease, PCOS, chronic stress), perimenopausal women whose estrogen has declined (estrogen suppresses VCAM-1, ICAM-1, and NF-κB, key inflammatory mediators), and women with significant caregiver allostatic load all have elevated hs-CRP from mechanisms that standard risk calculators do not capture.

Targets:

• Below 1.0 mg/L: low cardiovascular risk
• 1.0-3.0 mg/L: intermediate risk, warranting attention to modifiable inflammatory drivers (dental health, sleep, visceral fat, dietary pattern)
• Above 3.0 mg/L: high inflammatory cardiovascular risk, particularly if LDL or ApoB is also elevated

Caveat: hs-CRP rises with any acute illness, infection, or injury. It should not be measured during illness. If elevated, confirm with a repeat measurement 2-4 weeks later when well.

Number Five: Lp(a)

What it is: Lipoprotein(a) is a genetically determined lipoprotein variant with an additional protein (apolipoprotein(a)) attached to the LDL core. It has unique thrombogenic properties that standard LDL does not share, it inhibits fibrinolysis (clot breakdown) and promotes endothelial inflammation. 5 / Solid

Why it matters: Lp(a) above 50 mg/dL (or 100 nmol/L) independently increases cardiovascular risk 1.5-3 fold. It is present in elevated levels in approximately 20% of the general population and at higher rates in Black women specifically (a significant cardiovascular health equity gap). Elevated Lp(a) is associated with premature cardiovascular disease, calcific aortic stenosis, and peripheral artery disease.

Critically: Lp(a) is not reduced by statins, diet changes, exercise, or standard lipid-lowering therapy. A woman with elevated Lp(a) and LDL of 115 may need statin therapy at a lower LDL threshold than guidelines would otherwise suggest, because her total atherogenic burden (LDL + Lp(a)) exceeds what the LDL number alone captures.

One lifetime measurement: Lp(a) is genetically determined and does not change meaningfully with lifestyle. One measurement before age 50 (ideally earlier if family history of premature cardiovascular disease) is sufficient for lifetime risk stratification. New pharmacological options (pelacarsen, olpasiran) targeting Lp(a) are in late-stage clinical trials, women with elevated Lp(a) who are documented in medical records will be candidates when these agents become available.

Target: Below 50 mg/dL (below 100 nmol/L on the molar assay, which is more accurate). Request Lp(a) in mg/dL AND nmol/L to avoid unit confusion between labs.

When five borderline numbers are worse than one abnormal number

Each of the five numbers above has a threshold — above 90 for ApoB, above 130/80 for blood pressure, above 10 for fasting insulin, above 1.0 for hs-CRP, above 50 for Lp(a). Those thresholds treat each number in isolation. The clinical reality is that five borderline values constitute a qualitatively different cardiovascular picture than one abnormal value in an otherwise clean panel.

Consider a 49-year-old perimenopausal woman with:

• ApoB: 92 mg/dL (just above the 90 threshold)
• Blood pressure: 128/82 (just above 130/80 — or close, and trending up)
• Fasting insulin: 11 uIU/mL (mildly elevated)
• hs-CRP: 1.6 mg/L (intermediate range)
• Lp(a): 38 mg/dL (below the 50 mg/dL threshold, but not negligible)

None of those numbers would trigger immediate intervention in isolation. Individually, each might be described as “borderline” or “worth monitoring.” Together, they describe a metabolic and inflammatory environment — insulin resistance driving small dense LDL (reflected in the elevated ApoB despite modest LDL), systemic inflammation, rising blood pressure, and a meaningful Lp(a) contribution that the absolute value understates when combined with high ApoB — that represents real and accumulating cardiovascular risk.

The Pooled Cohort Equation, the standard 10-year risk calculator, would miss this entirely. It does not use ApoB, fasting insulin, hs-CRP, or Lp(a). It would likely calculate a 10-year risk of 4-6% and classify this woman as “low risk.” The five numbers together tell a different story: this is a woman whose cardiovascular trajectory is moving in the wrong direction across multiple pathways simultaneously, at the most vulnerable endocrine transition of her life. 5 / Solid

The compound pattern to recognize: Elevated fasting insulin + elevated ApoB + elevated hs-CRP is the insulin-resistance-driven inflammatory atherogenic phenotype. It is disproportionately common in perimenopausal women because visceral fat redistribution accelerates with estrogen decline, and visceral fat drives all three: insulin resistance (fasting insulin up), dyslipidemia (ApoB up), and inflammation (hs-CRP up). This phenotype has a worse cardiovascular prognosis than an equivalent LDL elevation in the absence of insulin resistance and inflammation, and it is almost invisible on standard labs.

Sex-specific targets and when the standard thresholds do not apply

The targets above are derived largely from population studies. Several specific scenarios warrant tighter targets or different interpretive frameworks for women.

Blood pressure targets after preeclampsia: Women with a history of preeclampsia have a 2-4 fold elevated lifetime risk of cardiovascular disease, independent of other risk factors. 5 / Solid For these women, a blood pressure of 125/80 is not reassuring in the way it might be for a woman without that history. The 2021 ACC/AHA guidelines recommend that history of preeclampsia be treated as a cardiovascular risk enhancer — meaning lower blood pressure thresholds should prompt intervention discussion earlier. Women with prior preeclampsia who have blood pressure creeping above 120/75 warrant earlier monitoring, not a “come back in a year.”

ApoB targets in women with prior gestational diabetes: Gestational diabetes is a powerful predictor of future type 2 diabetes and cardiovascular disease. Women who had gestational diabetes and have subsequently developed insulin resistance should target ApoB below 70 mg/dL rather than below 90, because their cardiovascular risk trajectory starts higher. Their fasting insulin and ApoB should be tracked together — rising insulin driving the atherogenic small dense LDL phenotype is particularly likely in this group.

Lp(a) with elevated ApoB — the multiplicative interaction: An Lp(a) of 45 mg/dL (just below the 50 mg/dL threshold) in a woman with ApoB of 95 mg/dL and hs-CRP of 2.1 mg/L is clinically more concerning than the same Lp(a) in a woman with ApoB of 65 and no inflammation. The Lp(a) contribution to atherogenic particle burden adds to ApoB rather than substituting for it. When ApoB is high, even sub-threshold Lp(a) levels contribute meaningfully. Some preventive cardiologists use ApoB + Lp(a) nmol/L as a combined atherogenic particle burden estimate — a practice not yet formalized in guidelines but supported by the biology. 4 / Promising

hs-CRP interpretation in women with autoimmune disease: Women with rheumatoid arthritis, lupus, psoriasis, or other chronic inflammatory conditions have baseline hs-CRP elevations that reflect disease activity rather than primary cardiovascular inflammation — but the cardiovascular risk from autoimmune-related vascular inflammation is real and distinct. For these women, hs-CRP monitoring should be interpreted alongside disease activity markers; a drop in hs-CRP with disease control is genuinely cardioprotective, while persistent elevation despite treatment warrants cardiovascular risk discussion with the treating rheumatologist.

When to test: timing by age and life stage

The five numbers are not all “get it once and you are done” — they have different testing cadences and different triggers for earlier evaluation.

Before 40: Get Lp(a) once — it does not change, so this single measurement informs all future risk conversations. Get a baseline ApoB and fasting insulin at 35-38 in the presence of any of: family history of premature cardiovascular disease (first-degree relative with event before 55 in men, before 65 in women), personal history of PCOS, obesity or significant weight gain since college, prior gestational diabetes, prior preeclampsia. These are not “wait until 45” situations.

At perimenopause onset (typically 44-48): This is the highest-priority testing window for women who have not yet established baseline values. The menopausal transition is the moment when ApoB begins to rise, blood pressure begins to rise, fasting insulin worsens with visceral fat redistribution, and hs-CRP increases with estrogen loss. Getting all five numbers at the beginning of perimenopause — even if a woman had a clean panel at 40 — establishes the trajectory before events occur. 5 / Solid

Repeat testing cadence once established:

• ApoB: every 1-2 years if at target, every 6-12 months if above target or after starting/changing lipid therapy
• Blood pressure: home monitoring is continuous; clinic review at each annual visit
• Fasting insulin: every 1-2 years if normal and no new metabolic changes; more frequently if above 10 or if weight has increased
• hs-CRP: annual if previously elevated; every 2-3 years if consistently below 1.0
• Lp(a): once in a lifetime is sufficient; no repeat needed

Triggers for out-of-cycle testing: New diagnosis of PCOS at any age (get all five immediately), pregnancy complicated by gestational diabetes or preeclampsia (get all five at 6-12 weeks postpartum and establish follow-up), significant weight gain over 6 months (get fasting insulin, ApoB, hs-CRP), new diagnosis of autoimmune disease (add hs-CRP to follow-up labs), family history of heart attack emerging in a sibling before 55 (get Lp(a), ApoB immediately regardless of age).

How to get all five numbers

Most require separate orders, they are not part of standard annual labs.

ApoB: Usually covered by insurance when ordered alongside a lipid panel. Request explicitly: “I would like ApoB added to my lipid panel.”

Blood pressure: Measure yourself. A quality home upper-arm cuff (Omron is the most validated brand) costs $35-60. Measure morning and evening for one week and bring the log.

Fasting insulin: Requires 8-12 hour fasting, same as the fasting glucose order. May not be covered by all insurance plans without a specific diagnosis code. Request as “fasting insulin to assess insulin sensitivity.”

hs-CRP: Standard lab test, widely available. Request as “high-sensitivity CRP” or “hsCRP” specifically, standard CRP is not sensitive enough for cardiovascular risk stratification.

Lp(a): Single-test order. May require physician justification for insurance coverage; some insurers cover it when there is family history of premature cardiovascular disease or unexplained high LDL. Direct-to-consumer options: LabCorp Patient Direct, Quest Direct, Function Health all offer Lp(a) testing.

What to do this week

The five numbers above are not abstract aspirations. Here is the specific sequence of actions that turns this article into a medical record.

Step 1: Pull up your most recent lab results. Look for ApoB, fasting insulin, hs-CRP, and Lp(a) by name. If they are not there, they were not ordered. Write down your most recent LDL, HDL, triglycerides, fasting glucose, and blood pressure reading — these are typically present and give partial context.

Step 2: Buy a home blood pressure cuff if you do not have one. Upper arm models validated for home use (Omron Platinum, Omron Bronze) are the clinical standard. Measure tomorrow morning: wake up, use the bathroom, sit quietly for 5 minutes, take three readings 1 minute apart, record all three. Do the same in the evening. One week of morning and evening readings gives your physician far more useful data than any clinic measurement.

Step 3: Contact your physician’s office and make a specific request. You do not need a new appointment for lab orders in most practices. A patient portal message requesting specific labs is appropriate. The message can say: “I would like the following added to my next labs: ApoB, fasting insulin, high-sensitivity CRP (hs-CRP), and Lp(a). I want to establish cardiovascular baseline values. Please let me know if you need any additional information or a visit to discuss.”

Step 4: Fast before the blood draw. ApoB, fasting insulin, and a meaningful lipid panel all require a 10-12 hour fast. Most morning lab draws work if you stop eating by 9 PM the night before and go in the next morning before eating. Drink water normally. Take your usual medications unless told otherwise.

Step 5: Record your numbers and what they mean before your next visit. When the results return, write down the actual values and the targets from this article. Bring the list to your next appointment. The conversation you want to have is: “My ApoB came back at X. I understand the target for women my age is below 90, or below 70 if I have additional risk factors. Given my history of [fill in as applicable: preeclampsia, gestational diabetes, PCOS, family history], which target applies to me, and what is the plan if I am above it?” That is the physician conversation that shifts cardiovascular care from reactive to preventive.

What these numbers are not: They are not a diagnosis. A high ApoB does not mean a heart attack is coming. A high fasting insulin does not mean you have diabetes. What elevated values mean is that a risk is present and modifiable — and that you now know about it before an event forces the conversation.

Related reading

For the full women’s cardiac lab panel: The Women’s Cardiac Screening Lab Panel.

For the ApoB and Lp(a) specifics: ApoB and Lp(a) in Women.

For the annual physical tests that supplement these five: Your Annual Physical Was ‘Normal’.